Taysha Gene Therapies EPS - Earnings per Share 2020-2024 | TSHA
Taysha Gene Therapies eps - earnings per share from 2020 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Taysha Gene Therapies Annual EPS |
| 2023 |
$-0.96 |
| 2022 |
$-3.78 |
| 2021 |
$-4.64 |
| 2020 |
$-3.40 |
| 2019 |
$0.00 |
| Taysha Gene Therapies Quarterly EPS |
| 2024-09-30 |
$-0.10 |
| 2024-06-30 |
$-0.09 |
| 2024-03-31 |
$-0.10 |
| 2023-12-31 |
$0.63 |
| 2023-09-30 |
$-0.93 |
| 2023-06-30 |
$-0.38 |
| 2023-03-31 |
$-0.28 |
| 2022-12-31 |
$-0.96 |
| 2022-09-30 |
$-0.65 |
| 2022-06-30 |
$-0.85 |
| 2022-03-31 |
$-1.32 |
| 2021-12-31 |
$-1.33 |
| 2021-09-30 |
$-1.35 |
| 2021-06-30 |
$-1.09 |
| 2021-03-31 |
$-0.87 |
| 2020-12-31 |
$0.33 |
| 2020-09-30 |
$-1.28 |
| 2020-06-30 |
$-1.95 |
| 2020-03-31 |
$-0.50 |
| 2019-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.379B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
